Physician profile
Scott Leone
NPI 1073613907
$15,922.40
in general payments reported to CMS, 2019-2025
33 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,115 · 2020: $2,186 · 2021: $2,963 · 2022: $1,905 · 2023: $1,882 · 2024: $2,452 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,728 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,728.30 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,304.25 | 2021-2025 | |
| Novo Nordisk INC | $2,634.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,180.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,299.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,172.70 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $783.84 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $683.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $603.09 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $583.45 | 2020-2021 | |
| Pfizer INC. | $568.58 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $402.74 | 2019-2025 | Contrave, Onzetra Xsail, Nexletol |
| Allergan, INC. | $204.26 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.59 | 2019-2025 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company Ltd. | $188.58 | 2022 | |
| Medicure Pharma INC. | $164.84 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $151.75 | 2020 | |
| Cequr Corporation | $132.00 | 2023 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $124.99 | 2019 | |
| Lundbeck LLC | $119.62 | 2023 | Vyepti |
| Exact Sciences Corporation | $71.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Seqirus USA INC | $55.50 | 2019-2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $38.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.29 | 2019-2021 | |
| Merz North America, INC. | $31.62 | 2019 | |
| Viiv Healthcare Company | $28.30 | 2022 | |
| Merck Sharp & Dohme LLC | $28.28 | 2019 | |
| Orexo US, INC. | $25.12 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.43 | 2020 | |
| Ardelyx, INC. | $22.31 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $19.72 | 2024 | Strensiq |
| Boston Scientific Corporation | $15.91 | 2024 | Bodyguardian |
| Shire North American Group INC | $15.60 | 2019 | |
| Tactile Systems Technology INC | $15.10 | 2024 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Leone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.